CAS No. 8001-54-5. Consists of Benzyl (dodecyl) dimethyl ammonium chloride (approx. 65%) and Benzyl (tetradecyl) dimethyl ammonium chloride (approximately 35%). Contains approximately 95% active ingredients.
Novo Nordisk Pharmatech A/S is a global and leading manufacturer of pharmaceutical ingredients for the pharmaceutical and biopharmaceutical industries. The company specialises in producing quaternary ammonium compounds (Quats) used as active pharmaceutical ingredients (APIs) and excipients, and Recombinant Insulin for use in cell culture media to enhance cell growth and viability and productivity.
Novo Nordisk Pharmatech helps the world’s largest pharmaceutical and biopharmaceutical industries reducing their risk for raw materials by using pharma-grade products with a high level of consistency, purity, quality, and reliability.
The mission is to enable better medicines by providing sustainable pharmaceutical materials through innovative and customised solutions.
High-purity insulin for cell proliferation
Novo Nordisk Pharmatech’s high purity, non-therapeutic insulin is sourced directly from parent company Novo Nordisk, the world’s largest insulin producer. It consists of insulin human crystals, biosynthetically produced by recombinant microbial expression in yeast.
Novo Nordisk Pharmatech
Recombinant Insulin stimulates the proliferation of cells, enhances the yield, and is a key component in serum-free growth media for mammalian cells. Insulin Human AF is used to manufacture monoclonal antibodies, virus vaccines, gene therapy products and other biological drug products approved by regulatory bodies worldwide, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Novo Nordisk Pharmatech’s Insulin Human AF is manufactured under internal quality systems, based on ISO 9001 and current good manufacturing practice (cGMP). It is analysed according to the current European (Ph Eur) and US (USP) Pharmacopoeias. The product is manufactured in Novo Nordisk’s parent cGMP facilities, packaged in high-density polyethylene (HDPE) bottles, and supplied by Novo Nordisk Pharmatech A/S.
Insulin Human AF has a shelf life of 60 months and the company has enough packed off-the-shelf Insulin Human AF in stock for at least five months of consumption, to be able to respond immediately to your specific requirements.
With Insulin Human AF from Novo Nordisk Pharmatech, you avoid the risk of impurities such as mycoplasmas, which can pass line to line from the upstream bioreactor and contaminate your whole line.
Pharmaceutical-grade quaternary ammonium compounds
As the world’s leading supplier of pharmaceutical grade quaternary ammonium compounds (Quats), Novo Nordisk Pharmatech provides only the best and safest ingredients for the pharmaceutical and personal care industries. The Quats products are sold in more than 70 countries across Europe, Asia, North America, South America and Africa.
Novo Nordisk Pharmatech is a specialist and dedicated manufacturer of Quats in an unequalled, full cGMP grade ensuring exceptionally high purity and batch-to-batch consistency. Their Quats product range (including Benzalkonium Chloride, Cetrimide and Cetrimonium Bromide/CTAB) is suited for a wide range of pharmaceutical applications that require high purity and quality, such as vaccine production and as preservatives (excipients) or APIs in many ophthalmic, nasal, oral and topical drugs and in a variety of solutions, ointments, gels and creams.
Novo Nordisk Pharmatech’s Quats have excellent antimicrobial and surface-active properties, and are active against a broad spectrum of microorganisms, such as gram + and – & acid-fast bacteria, yeasts, moulds and enveloped viruses such as HIV, herpes and corona. They are effective through a wide pH range, are surface-active/adhesive cationic agents and do not add unpleasant odours or colours to finished formulations.
The multi-compendial range of Quats complies with the highest regulatory guidelines, including ICH Q7, the European Pharmacopoeia (Ph Eur) and the United States Pharmacopoeia (USP). Some Quats products also follow the Japanese, British or Chinese Pharmacopoeias.
Combining high-purity products and regulatory services have made the company an approved supplier to many of the world’s leading pharmaceutical companies. With more than 70 years of experience producing Quats and more than 30 years of cGMP manufacturing, Novo Nordisk Pharmatech delivers the same high-quality products batch after batch.
Rigorous quality and control checks
Being cGMP certified, Novo Nordisk Pharmatech ensures that every aspect of the manufacturing process is in control – from its own suppliers to the finished product.
All manufacturing is carried out in accordance with cGMP (ICH Q7), ISO9001 Standard Operating Procedures (SOP) Qualification and Validation. The filling of Quats is performed under full cleanroom conditions, while Insulin Human AF is packed in a classified (Class C) facility. High product quality is ensured through efficient quality control, rigorous training systems, well-established SOPs and quality analysis carried out by highly experienced professionals.
The cornerstone of our quality organisation is a stringent Quality Management System (QMS) to ensure the right quality products with a high degree of consistency. Novo Nordisk Pharmatech’s QMS complies with DS/EN ISO 9001 in all aspects of the value chain and has received excellent ratings in audits from both customers and authorities, including the FDA and EMA.
A comprehensive documentation package and tailored support, which continues through the whole product life cycle, gives you total peace of mind. The company provides a one-stop compliance and regulatory package, providing you with upfront access to certificates from authorities (including cGMP, ISO 9001, 14001 and 45001), qualification dossiers, statements and declarations, stability, and analysis documents, and much more. They also support their customers well after supplier qualification and delivery and through the whole product life cycle in case of any problems or issues.
Environmentally conscious API manufacturing
Environmental challenges have never been more critical or more urgent than they are today, and Novo Nordisk Pharmatech has proudly been carbon-neutral since 2018. Supplied with renewable energy produced by windmills and gas consumption from biogas certificates, we have zero carbon emissions from energy consumption.
Novo Nordisk Pharmatech is also a part of Novo Nordisk’s bold environmental strategy, Circular for Zero. The ambition is to have zero environmental impact by 2030. To achieve zero impact, both up and down our supply chain, working with our suppliers is paramount. With both current and future suppliers, we will collaborate proactively to embed circular thinking across the value chain and switch to circular sourcing and procurement.
About Novo Nordisk Pharmatech
Novo Nordisk Pharmatech A/S was established in 1949 as Ferrosan Fine Chemicals, part of the Ferrosan Group. The Ferrosan Group was acquired by Novo Industries in 1986, becoming part of Novo Nordisk A/S with the 1989 merger of Novo with Nordisk Gentofte.
On September 1, 2015, the company changed its name to Novo Nordisk Pharmatech A/S, operating as a division of Novo Nordisk A/S from Køge, south of Copenhagen.
The entire value chain, from research and development, manufacturing, quality assurance and quality control to sales and marketing, is located on-site in Køge, giving the company significant advantages in terms of agility.
More than 70 years of experience have given Novo Nordisk Pharmatech the know-how to ensure maximum product purity and keeping impurities to even lower levels than pharmacopeial standards. This has made the company a leading global supplier of high-quality ingredients, enabling the customers to make even better medicines.
CAS No. 8001-54-5. Consists of Benzyl (dodecyl) dimethyl ammonium chloride (approx. 65%) and Benzyl (tetradecyl) dimethyl ammonium chloride (approximately 35%). Contains approx. 50% active ingredients.
CAS No. 8001-54-5. Custom design solution consisting of Benzyl (dodecyl) dimethyl ammonium chloride (approximately 65%) and Benzyl (tetradecyl) dimethyl ammonium chloride (approximately 35%). Contains approximately 17% active ingredients.
CAS No. 8001-54-5. Custom design product consisting of Benzyl (dodecyl) dimethyl ammonium chloride (approximately 64%), Benzyl (tetradecyl) dimethyl ammonium chloride (approximately 34%) and Benzyl (hexadecyl) dimethyl ammonium chloride (approximately 2%-3%). Contains approximately 95% active ingredients.
Also known as Cetrimide, Cetrimoni Bromidum and Tetradecyl Trimethyl Ammonium Bromide (TTAB), FeF® Strong Cetrimide Solution 40% BP Pharma with Ethanol FeF® (CAS No. 1119-97-7) consists of approximately 20% dodecyl trimethyl ammonium bromide, approximately 70% trimethyl tetradecyl ammonium bromide and around 10% hexadecyl trimethyl ammonium bromide.
Also known as Cetrimide, Cetrimoni Bromidum and Tetradecyl trimethyl ammonium bromide (TTAB), FeF® Strong Cetrimide Solution 40% BP Pharma with isopropyl alcohol (CAS No. 1119-97-7) consists of around 20% dodecyl trimethyl ammonium bromide and approcimately 80% trimethyl tetradecyl ammonium bromide, as well as approximately 7.5% volume by volume (v/v) isopropyl alcohol.
The Chinese hamster ovary (CHO) cell line is widely used for the production of recombinant proteins due to its high growth capacity and productivity, as well as other cell lines derived later than CHO
For more than 30 years, the National Research Council of Canada has been helping clients develop, optimise, scale-up and transfer bioprocesses to produce biologics and vaccines.
Novo Nordisk Pharmatech A/S has entered into an agreement with IMCoPharma a.s. to distribute pharmaceutical grade quaternary ammonium compounds (Quats) to the healthcare industry in the Russian market and CIS countries.
Novo Nordisk Pharmatech is developing a portfolio of speciality enzymes and customised resins for the biopharma and regenerative medicines market.
Our cGMP manufacturing facilities make Novo Nordisk Pharmatech the leading supplier of pharmaceutical-grade Quats for a wide range of applications.
If you manufacture products for markets beyond your own, ensuring regulatory compliance can be a particular challenge: from staying up to date with changes to navigating language barriers, or even meeting requirements above the official guidelines.
Did you know that our Insulin Human AF is the same high-quality insulin supplied to patients all around the world for therapeutic use?
Emisphere Technologies has entered into a definitive agreement with Novo Nordisk, whereby the latter will acquire Emisphere for $1.35b in cash on a cash-free, debt-free basis.
Supply chain safety, quality and reliability are essential to our Quats and Insulin Human clients, and we can help secure each supply chain, from sourcing raw materials to delivering products as promised, even in a global emergency.
Get peace of mind for your full product life cycle with a pharma organisation like Novo Nordisk Pharmatech, who ensure quality Quats and Insulin Human AF with zero compromises.
Within the biopharma industry, consistency is essential in regards to products, as well as suppliers. We spoke with two from Thermo Fisher Scientific specialists concerning how they meet their clients' requests alongside Novo Nordisk Pharmatech.
Regulations are tightening, and supply chains are shifting, so we asked a Brenntag specialist with more than four decades of expertise in the industry how Brenntag and Novo Nordisk Pharmatech can assist the US pharma market currently and in future.
Novo Nordisk Pharmatech A / S is pleased to announce the opening of a new branch in Singapore at 152 Beach Road #17-04 The Gateway East, which opened on September 2019.
The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today’s bioprocess challenges.
Novo Nordisk Pharmatech and DKSH have partnered to provide high-quality current good manufacturing practice (cGMP) quaternary ammonium compounds (quats) in eleven markets across the Asia Pacific (APAC).
Novo Nordisk Pharmatech has entered an agreement with Signet Chemical Corporation for the distribution of its pharmaceutical range of quaternary ammonium compounds (FEF® Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.
The 2017 Bioprocessing Summit in Boston, MA, convenes more than 1,000 international bioprocess professionals to share practical solutions for today’s bioprocess challenges.
Novo Nordisk Pharmatech invites you to visit its booth (booth #12) at the 7th Annual Biologics Manufacturing Korea in Seoul, Korea
Join key industry players at CPhI North America, the meeting place for those seeking powerful partnerships to illuminate the path towards high-growth in the pharmaceutical industry.
Novo Nordisk Pharmatech has announced that it will be a part of the annual BioProcess International European Summit.
Novo Nordisk Pharmatech has announced it will be showcasing its innovative biologics and Insulin Human AF at the World Biosimilar Congress in Switzerland.
Novo Nordisk Pharmatech has announced it will be attending this year's European Antibody Congress, which will be held in Congress Center Basel in Switzerland.
Novo Nordisk has announced it will be present at CPhI Worldwide.
Novo Nordisk Pharmatech Showcases Recombinant Insulin at BioProcess International Conference and Exhibition
Novo Nordisk has announced it will be attending the BioProcess International conference and exhibition.
Novo Nordisk Pharmatech Selects Azelis to Distribute its Quaternary Ammonium Compounds in Germany, Spain, Portugal, the UK, and Ireland
Novo Nordisk Pharmatech has entered an agreement with Azelis for the distribution of quaternary ammonium compounds (quats) to the pharmaceutical and medical device markets in Germany, Spain Portugal, UK and Ireland.
Novo Nordisk has announced it will be attending CPhI North America, the meeting place for those seeking powerful partnerships to illuminate the path towards high-growth in the pharmaceutical industry.
Novo Nordisk has announced it will be attending the 25th European Society for Animal Cell Technology (ESACT) meeting.
Novo Nordisk Pharmatech has announced it will be attending the annual Cell Line Development and Engineering Asia at the Hilton Shanghai Hongqiao.
Novo Nordisk Pharmatech has announced it will be returning for the annual World Vaccine Congress.
Selectchemie expands its pharmaceutical, over the counter (OTC) and personal care product offering with Novo Nordisk Pharmatech's pharmaceutical-grade quaternary ammonium compounds for Switzerland, Austria, and Eastern European markets.
Novo Nordisk Pharmatech has announced it will be attending CHPI Worldwide to showcase its product portfolio.
Brenntag Specialties (BSI) has signed a distribution agreement for Novo Nordisk Pharmatech's Pharmaceutical Grade Quaternary Ammonium Compounds, to be marketed in the US and Peurto Rican personal care, over-the-counter (OTC), and pharmaceutical markets.
Novo Nordisk Pharmatech will be attending the BioProcess International European Summit from 12-13 April in Vienna, Austria.
To provide the best possible customer service, Novo Nordisk Pharmaceuticals now offers distribution from two separate warehouse locations that serve a global client base. One is located in Plainfield, Indiana, US, and the other facility is located near Copenhagen, Denmark.
Novo Nordisk Pharmatech will host a booth at this week's Biosimilars Asia.
The Danish Medicines Agency has recently renewed its cGMP certificate in accordance with EU GMP Part II (ICH Q7) for an additional three-year period.
Quaternary ammonium compounds (Quats) have excellent antimicrobial and surface-active properties, and have a very wide range of applications.
With the enforcement of the European Directive 2011/62/EU relating to medicinal products for human use regarding falsified medicinal products, new requirements are introduced for active substances.